Establishment of a Novel CD34+ Hematopoietic Stem Cell-Derived Xenograft Model of Hyperleukocytic Acute Myeloid Leukemia

Abstract

Hyperleukocytic acute myeloid leukemia (HLL) with high early mortality is difficult to therapy. The related research on HLL is still in its infancy, and the establishment of a patient derived xenograft (PDX) model of HLL has not been fully reported. In this study, we establish a CD34+ hematopoietic stem cell-derived xenograft model of HLL for further exploration. Our findings demonstrated that the leukemia cells were detected in peripheral blood, bone marrow, liver, and spleen tissues in mice after inoculation of patient-derived cells. By performing a comparative analysis of multiple experiments, we found the irradiation doses, injection cell counts, gene abnormal and the survival status of the enrolled patients affected the survival time in mice. We successfully established a novel CD34+ hematopoietic stem cell-derived xenograft model of HLL, which shows great promise for mechanistic research, drug screening, individualized therapy, clinical efficacy assessment and precision medicine in HLL.